BIO

Bio-Rad Laboratories, Inc. NYSE

Healthcare ·Medical - Devices ·US · bio-rad.com

$257.86

Mkt Cap $7.0B

52w Low $211.43 35.3% of range 52w High $343.12

50d MA $277.31 200d MA $292.34

P/E (TTM) 9.2x

EV/EBITDA 19.5x

P/B 0.9x

Debt/Equity 0.2x

ROE 10.2%

P/FCF 22.1x

RSI (14) —

ATR (14) —

Beta 1.16

50d MA $277.31

200d MA $292.34

Avg Volume 303.5K

About

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research te…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 30, 2026	AMC	1.97	1.89	-4.1%	280.12	-6.7%	-8.4%	-7.9%	—	—	—	—
Feb 12, 2026	AMC	2.57	2.51	-2.3%	292.42	-14.2%	-12.3%	-9.4%	-7.4%	-7.0%	-7.2%	—
Oct 29, 2025	AMC	2.30	2.26	-1.7%	319.47	-1.1%	-4.7%	+0.0%	-2.5%	-2.7%	-3.0%	—
Jul 31, 2025	AMC	1.93	2.61	+35.2%	241.95	+12.0%	+17.6%	+14.4%	+12.5%	+9.2%	+9.6%	—
May 1, 2025	AMC	1.73	2.54	+46.8%	240.43	+4.0%	-1.7%	-0.1%	-3.7%	-3.3%	+0.2%	—
Feb 13, 2025	AMC	2.86	2.90	+1.4%	306.36	-1.4%	-9.5%	-7.6%	-7.4%	-6.8%	-8.6%	—
Oct 30, 2024	AMC	1.28	2.01	+57.0%	330.58	+5.4%	+8.4%	+11.4%	+11.6%	+13.2%	+12.8%	—
Aug 1, 2024	AMC	2.12	3.11	+46.7%	341.25	-1.4%	-1.6%	-3.7%	-4.2%	-6.6%	-3.8%	—
May 7, 2024	AMC	2.15	2.29	+6.5%	279.91	-2.6%	-4.2%	-0.9%	+0.7%	+2.0%	+5.0%	—
Feb 15, 2024	AMC	2.93	3.10	+5.8%	328.73	+6.5%	+3.6%	+4.6%	+3.0%	+3.0%	+2.8%	—
Oct 26, 2023	AMC	2.87	2.33	-18.8%	291.53	-5.9%	-7.2%	-7.6%	-5.6%	-4.8%	-3.5%	—
Aug 3, 2023	AMC	2.55	3.00	+17.6%	401.80	+1.7%	-0.4%	-0.1%	+0.3%	-1.3%	-1.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$280.12	$261.47	-6.7%	-8.4%	—	—	—	—
Apr 7	Citigroup	Downgrade	Buy → Neutral	—	$278.85	$272.21	-2.4%	-0.3%	+0.8%	-0.5%	+0.1%	+3.3%
Oct 30	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$319.47	$316.00	-1.1%	-4.7%	+0.0%	-2.5%	-2.7%	-3.0%
Oct 30	Citigroup	Maintains	Buy → Buy	—	$319.47	$316.00	-1.1%	-4.7%	+0.0%	-2.5%	-2.7%	-3.0%
Aug 1	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$241.95	$270.93	+12.0%	+17.6%	+14.4%	+12.5%	+9.2%	+9.6%
Aug 1	RBC Capital	Maintains	Outperform → Outperform	—	$241.95	$270.93	+12.0%	+17.6%	+14.4%	+12.5%	+9.2%	+9.6%
Jun 9	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$219.42	$222.81	+1.5%	+2.8%	+5.1%	+4.9%	+5.9%	+3.4%
May 2	Citigroup	Maintains	Buy → Buy	—	$240.43	$250.00	+4.0%	-1.7%	-0.1%	-3.7%	-3.3%	+0.2%
May 2	UBS	Maintains	Buy → Buy	—	$240.43	$250.00	+4.0%	-1.7%	-0.1%	-3.7%	-3.3%	+0.2%
May 2	RBC Capital	Maintains	Outperform → Outperform	—	$240.43	$250.00	+4.0%	-1.7%	-0.1%	-3.7%	-3.3%	+0.2%
Apr 17	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$245.21	$243.06	-0.9%	-2.9%	-3.4%	-0.1%	+1.5%	+1.8%
Feb 12	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$314.73	$310.70	-1.3%	-0.8%	-2.7%	-11.9%	-10.0%	-9.8%
Jan 14	RBC Capital	Maintains	Outperform → Outperform	—	$351.70	$351.70	+0.0%	-2.7%	-2.8%	-2.1%	-2.6%	+0.6%
Dec 9	RBC Capital	Maintains	Outperform → Outperform	—	$325.50	$324.83	-0.2%	+6.2%	+4.4%	+4.9%	+4.5%	+3.3%
Oct 31	RBC Capital	Maintains	Outperform → Outperform	—	$330.58	$348.47	+5.4%	+8.4%	+11.4%	+11.6%	+13.2%	+12.8%
Oct 31	Citigroup	Maintains	Buy → Buy	—	$330.58	$348.47	+5.4%	+8.4%	+11.4%	+11.6%	+13.2%	+12.8%
Oct 1	Citigroup	Upgrade	Neutral → Buy	—	$334.58	$338.55	+1.2%	+0.9%	+2.4%	+0.8%	+2.7%	+1.9%
Aug 16	RBC Capital	Maintains	Outperform → Outperform	—	$325.62	$325.59	-0.0%	-0.0%	+0.2%	-2.1%	-2.9%	-4.8%
Aug 2	RBC Capital	Maintains	Outperform → Outperform	—	$341.25	$336.54	-1.4%	-1.6%	-3.7%	-4.2%	-6.6%	-3.8%
Aug 2	Citigroup	Maintains	Neutral → Neutral	—	$341.25	$336.54	-1.4%	-1.6%	-3.7%	-4.2%	-6.6%	-3.8%
May 8	UBS	Maintains	Buy → Buy	—	$279.91	$272.52	-2.6%	-4.2%	-0.9%	+0.7%	+2.0%	+5.0%
Apr 3	Citigroup	Downgrade	Buy → Neutral	—	$328.72	$322.13	-2.0%	-0.2%	-1.8%	-1.3%	-0.7%	+3.3%
Feb 16	UBS	Maintains	Buy → Buy	—	$328.73	$350.00	+6.5%	+3.6%	+4.6%	+3.0%	+3.0%	+2.8%
Feb 16	RBC Capital	Maintains	Outperform → Outperform	—	$328.73	$350.00	+6.5%	+3.6%	+4.6%	+3.0%	+3.0%	+2.8%
Aug 7	Wells Fargo	Maintains	Overweight → Overweight	—	$400.00	$398.54	-0.4%	+0.4%	+0.7%	-0.8%	-0.5%	-0.7%
Aug 4	Credit Suisse	Maintains	Outperform → Outperform	—	$401.80	$408.79	+1.7%	-0.4%	-0.1%	+0.3%	-1.3%	-1.0%
Aug 4	RBC Capital	Maintains	Outperform → Outperform	—	$401.80	$408.79	+1.7%	-0.4%	-0.1%	+0.3%	-1.3%	-1.0%
May 8	RBC Capital	Maintains	Outperform → Outperform	—	$385.24	$384.69	-0.1%	-1.8%	-4.8%	-5.1%	-5.4%	-3.3%
May 8	Citigroup	Maintains	Buy → Buy	—	$385.24	$384.69	-0.1%	-1.8%	-4.8%	-5.1%	-5.4%	-3.3%
May 5	Credit Suisse	Maintains	Outperform → Outperform	—	$462.61	$400.00	-13.5%	-16.7%	-18.2%	-20.7%	-21.0%	-21.2%
Feb 17	Credit Suisse	Maintains	Outperform → Outperform	—	$455.91	$455.00	-0.2%	+6.0%	+2.7%	+4.4%	+6.8%	+5.3%
Feb 17	RBC Capital	Maintains	Outperform → Outperform	—	$455.91	$455.00	-0.2%	+6.0%	+2.7%	+4.4%	+6.8%	+5.3%
Dec 7	RBC Capital	Maintains	Outperform → Outperform	—	$399.59	$401.97	+0.6%	+1.1%	+5.1%	+4.1%	+4.7%	+8.9%
Oct 28	Credit Suisse	Maintains	Outperform → Outperform	—	$385.02	$365.70	-5.0%	-8.0%	-8.7%	-6.9%	-7.5%	-5.2%
Aug 25	Credit Suisse	Maintains	Outperform → Outperform	—	$499.09	$505.55	+1.3%	+3.1%	-0.8%	-2.2%	-3.1%	-2.8%
Jul 8	Citigroup	Maintains	Buy → Buy	—	$512.54	$506.13	-1.3%	+0.9%	+1.8%	-2.4%	-2.6%	-4.8%
Jul 30	Wells Fargo	Maintains	Overweight → Overweight	—	$707.13	$713.11	+0.8%	+4.6%	+4.1%	+5.5%	+7.8%	+8.0%
Feb 12	Citigroup	Maintains	Buy → Buy	—	$643.81	$650.00	+1.0%	+2.9%	+0.9%	+1.8%	+1.2%	-1.1%
Feb 5	Jefferies	Maintains	Buy → Buy	—	$605.01	$608.62	+0.6%	+1.9%	+3.9%	+5.2%	+4.4%	+6.4%
Jul 31	Citigroup	Maintains	Buy → Buy	—	$535.60	$524.93	-2.0%	-2.0%	-0.9%	-1.6%	-1.5%	-1.9%
May 21	Wells Fargo	Maintains	Overweight → Overweight	—	$472.94	$474.90	+0.4%	-1.3%	-0.1%	+1.7%	-0.5%	+0.9%
May 7	Citigroup	Maintains	Buy → Buy	—	$449.99	$464.46	+3.2%	+2.3%	+1.4%	+4.5%	+2.6%	+1.1%
Apr 20	Citigroup	Maintains	Buy → Buy	—	$427.21	$426.12	-0.3%	-0.5%	-2.2%	-1.3%	-0.9%	+1.4%
Mar 30	Wells Fargo	Maintains	Overweight → Overweight	—	$322.41	$326.18	+1.2%	+8.3%	+8.7%	+3.9%	+11.9%	+13.5%
Mar 26	Barclays	Maintains	Overweight → Overweight	—	$333.00	$337.37	+1.3%	+2.5%	-3.2%	+4.8%	+5.3%	+0.6%
Mar 20	Citigroup	Maintains	Buy → Buy	—	$346.80	$347.35	+0.2%	-5.1%	-5.9%	-1.1%	-4.0%	-1.6%
Feb 14	Wells Fargo	Maintains	Overweight → Overweight	—	$379.34	$380.70	+0.4%	+6.4%	+7.4%	+7.8%	+7.8%	+5.6%
Jan 8	Wells Fargo	Maintains	Overweight → Overweight	—	$380.54	$384.25	+1.0%	+0.3%	+2.2%	+0.8%	+0.9%	+1.0%
Jan 7	Citigroup	Maintains	Buy → Buy	—	$372.03	$374.94	+0.8%	+2.3%	+2.6%	+4.5%	+3.1%	+3.3%
Aug 20	Goldman Sachs	Upgrade	Buy → Conviction Buy	—	$330.95	$336.90	+1.8%	+2.9%	+4.0%	+3.3%	+0.5%	+1.3%

Recent Filings

8-K · 5.02 !!! Very High

Bio-Rad Laboratories, Inc.Class A -- 8-K 5.02: Executive Change

Bio-Rad's departure of a key executive creates leadership uncertainty that could impact operational continuity and investor confidence, warranting caution until a qualified successor is named.

Apr 24

8-K · 7.01 ! Medium

Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure

Bio-Rad Laboratories disclosed updated financial information regarding its Sartorius AG investment following Sartorius's 2025 earnings release, providing investors transparency on this significant equity holding's performance.

Feb 19

8-K · 7.01 ! Medium

Bio-Rad Laboratories, Inc.Class A -- 8-K 7.01: Regulation FD Disclosure

Bio-Rad Laboratories disclosed supplemental earnings presentation materials under Regulation FD, providing investors with additional financial and operational details beyond standard earnings reports.

Feb 12

Data updated apr 24, 2026 9:39pm · Source: massive.com